News

Voyager Therapeutics’ Potential Gene Therapy Program for FA Moving Toward Pre-Clinical Stage

Voager Therapeutics has announced that its Friedreich’s ataxia program, VY-FXN01, is taking steps to initiate preclinical tests of its safety and effectiveness, the company expects to achieve in a two-year period the needed requirements to proceed to treatment testing in Friedreich’s ataxia patients. “Voyager’s exceptional performance and accomplishments during…